Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons.
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are characterized by intraneuronal deposition of the nuclear TAR DNA-binding protein 43 (TDP-43) caused by unknown mechanisms. Here, we studied TDP-43 in primary neurons under different stress conditions and found that only proteasome inhibition by MG-132 or lactacystin could induce significant cytoplasmic accumulation of TDP-43, a histopathological hallmark in disease. This cytoplasmic accumulation was accompanied by phosphorylation, ubiquitination and aggregation of TDP-43, recapitulating major features of disease. Proteasome inhibition produced similar effects in both hippocampal and cortical neurons, as well as in immortalized motor neurons. To determine the contribution of TDP-43 to cell death, we reduced TDP-43 expression using small interfering RNA (siRNA), and found that reduced levels of TDP-43 dose-dependently rendered neurons more vulnerable to MG-132. Taken together, our data suggests a role for the proteasome in subcellular localization of TDP-43, and possibly in disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“proteasome inhibition using MG-132 leads to the cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP-43) in cultured hippocampal and cortical neurons and in immortalized motor neurons (van Eersel et al., 2011).”
From Proteasome dysfunction induces muscle growth defects and protein aggregation (2014) · cites this paper as van Eersel et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 8×
“Since neurons are the primary cell type affected in FTLD-U and ALS, we tested the effects of proteasome inhibition on endogenous TDP-43 in primary cortical and hippocampal neurons or immortalized motor neurons.”
BackgroundResultInfluentialAssociation of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 1×
“Pathological protein aggregates are frequently surrounded by proteasomes and lysosomes, however, these fail to fully remove the deposits [44,45].”
BackgroundArai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732 · cited 1×
“Similar ubiquitin-positive inclusions are also found in motor neurons and some other neurons in ALS, and can contain either aggregated TDP-43 [11,12] and/or FUS [13].”
BackgroundTDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., et al. (2008) · Science · doi:10.1126/science.1154584 · Cited by 2,630 · cited 2×
“Cell culture, as well as yeast and animal models have provided insights into TDP-43 pathology [17,18,20,40,41,42].”
BackgroundBrooks, B. R. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90191-0 · Cited by 2,140 · cited 1×
“ALS often leads to death within three years of diagnosis [1,2].”
BackgroundMutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Self-citationThe roles of intracellular protein-degradation pathways in neurodegeneration
Rubinsztein, D. C. (2006) · Nature · doi:10.1038/nature05291 · Cited by 1,625 · cited 2×
“Proteasome dysfunction has been implicated in several neurodegenerative disorders, including ALS [43,46].”
BackgroundTARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., Velde, C. V., Bouchard, J.-P., Lacomblez, L., Pochigaeva, K., Salachas, F., et al. (2008) · Nature Genetics · doi:10.1038/ng.132 · Cited by 1,544 · cited 4×
“Cell culture, as well as yeast and animal models have provided insights into TDP-43 pathology [17,18,20,40,41,42].”
BackgroundResultInfluentialCruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512 · cited 1×
“Other more frequent pathogenic mutations have been described in genes including PGRN [36,37], VCP [38] and CHMP2B [39].”
BackgroundMutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474 · cited 2×
“Hence, FTLD-U cases with inclusions consisting of the protein TAR DNA-binding protein 43 (TDP-43) are termed FTLD-TDP, in contrast to FTLD-tau with tau inclusions, FTLD-FUS with inclusions containing fused in sarcoma (FUS) protein, and a smaller group of cases with deposits of unknown content termed FTLD-ubiquitin pro…”
BackgroundMcKhann, G. M. (2001) · Archives of Neurology · doi:10.1001/archneur.58.11.1803 · Cited by 1,472 · cited 1×
“In comparison, frontotemporal lobar degeneration (FTLD) is a heterogeneous group of neurodegenerative disorders, clinically characterized by behavioral changes and/or language abnormalities, which may also be accompanied by motor symptoms, such as parkinsonism [3,4] or ALS [3,5].”
BackgroundWatts, G. D. J., Wymer, J., Kovach, M. J., Mehta, S. G., Mumm, S., Darvish, D., Pestronk, A., Whyte, M. P., & Kimonis, V. E. (2004) · Nature Genetics · doi:10.1038/ng1332 · Cited by 1,391 · cited 1×
“Other more frequent pathogenic mutations have been described in genes including PGRN [36,37], VCP [38] and CHMP2B [39].”
BackgroundLewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371 · cited 1×
“This assisted in the development of both cell culture and animal models to investigate tau-related pathomechanisms [28,29,30,31].”
BackgroundThe prevalence of frontotemporal dementia
Ratnavalli, E., Brayne, C., Dawson, K., & Hodges, J. R. (2002) · Neurology · doi:10.1212/wnl.58.11.1615 · Cited by 1,157 · cited 1×
“FTLD is the second most common form of dementia presenting before the age of 65 [6].”
BackgroundCairns, N. J., Bigio, E. H., Mackenzie, I. R. A., Neumann, M., Lee, V. M.-Y., Hatanpaa, K. J., White, C. L., Schneider, J. A., Grinberg, L. T., Halliday, G., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0237-2 · Cited by 1,110 · cited 1×
“In comparison, frontotemporal lobar degeneration (FTLD) is a heterogeneous group of neurodegenerative disorders, clinically characterized by behavioral changes and/or language abnormalities, which may also be accompanied by motor symptoms, such as parkinsonism [3,4] or ALS [3,5].”
BackgroundMackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012 · cited 1×
“Hence, FTLD-U cases with inclusions consisting of the protein TAR DNA-binding protein 43 (TDP-43) are termed FTLD-TDP, in contrast to FTLD-tau with tau inclusions, FTLD-FUS with inclusions containing fused in sarcoma (FUS) protein, and a smaller group of cases with deposits of unknown content termed FTLD-ubiquitin pro…”
BackgroundSelf-citationTreatment of Ischemic Brain Damage by Perturbing NMDA Receptor- PSD-95 Protein Interactions
Aarts, M., Liu, Y., Liu, L., Besshoh, S., Arundine, M., Gurd, J. W., Wang, Y.-T., Salter, M. W., & Tymianski, M. (2002) · Science · doi:10.1126/science.1072873 · Cited by 999 · cited 1×
“Furthermore, we determined the toxicity of MG-132-mediated proteasome inhibition by propidium iodine (PI) uptake, a measure of cell death frequently used in neurons [47,48].”
MethodTDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916 · cited 1×
“. Furthermore, TDP-43 pathology is also observed in a proportion of patients with other neurodegenerative disorders such as Alzheimer's disease, but in a restricted anatomical distribution and at a much lower density”
BackgroundMutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia
Skibinski, G., Parkinson, N. J., Brown, J. M., Chakrabarti, L., Lloyd, S. L., Hummerich, H., Nielsen, J. E., Hodges, J. R., Spillantini, M. G., Thusgaard, T., et al. (2005) · Nature Genetics · doi:10.1038/ng1609 · Cited by 822 · cited 1×
“Other more frequent pathogenic mutations have been described in genes including PGRN [36,37], VCP [38] and CHMP2B [39].”
BackgroundPhosphorylated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Hasegawa, M., Arai, T., Nonaka, T., Kametani, F., Yoshida, M., Hashizume, Y., Beach, T. G., Buratti, E., Baralle, F., Morita, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21425 · Cited by 777 · cited 7×
“The inclusions in FTLDTDP and ALS contain both phosphorylated and ubiquitinated TDP-43 [11,53,54].”
BackgroundInfluentialOu, S. H., Wu, F., Harrich, D., García-Martínez, L. F., & Gaynor, R. B. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3584-3596.1995 · Cited by 758 · cited 1×
“It was first identified as a binding partner of the human immunodeficiency virus TAR DNA element [15].”
BackgroundVan Deerlin, V. M., Leverenz, J. B., Bekris, L. M., Bird, T. D., Yuan, W., Elman, L. B., Clay, D., Wood, E. M., Chen-Plotkin, A. S., Martinez-Lage, M., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70071-1 · Cited by 723 · cited 1×
“A pathogenic role for TDP-43 in disease is supported by the identification of mutations in TARDBP in familial and sporadic ALS [17,18,19,20,21,22,23].”
BackgroundNeuroblastoma × spinal cord (NSC) hybrid cell lines resemble developing motor neurons
Cashman, N. R., Durham, H. D., Blusztajn, J. K., Oda, K., Tabira, T., Shaw, I. T., Dahrouge, S., & Antel, J. P. (1992) · Developmental Dynamics · doi:10.1002/aja.1001940306 · Cited by 722 · cited 2×
“The immortalized motor neuron cell line NSC-34 was cultured as previously described [52].”
BackgroundMethodTDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration
Wegorzewska, I., Bell, S., Cairns, N. J., Miller, T. M., & Baloh, R. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908767106 · Cited by 706 · cited 1×
“Cell culture, as well as yeast and animal models have provided insights into TDP-43 pathology [17,18,20,40,41,42].”
BackgroundAnimal models of Alzheimer's disease and frontotemporal dementia
Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676 · cited 1×
“This assisted in the development of both cell culture and animal models to investigate tau-related pathomechanisms [28,29,30,31].”
BackgroundSelf-citationWinton, M. J., Igaz, L. M., Wong, M. M., Kwong, L. K., Trojanowski, J. Q., & Lee, V. M.-Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800342200 · Cited by 659 · cited 2×
“Cell culture, as well as yeast and animal models have provided insights into TDP-43 pathology [17,18,20,40,41,42].”
BackgroundUbiquitin, the proteasome and protein degradation in neuronal function and dysfunction
Tai, H.-C., & Schuman, E. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2499 · Cited by 532 · cited 5×
“Proteasome dysfunction has been implicated in several neurodegenerative disorders, including ALS [43,46].”
BackgroundInfluentialTau filament formation in transgenic mice expressing P301L tau
Götz, J., Chen, F., Barmettler, R., & Nitsch, R. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006531200 · Cited by 495 · cited 1×
“This assisted in the development of both cell culture and animal models to investigate tau-related pathomechanisms [28,29,30,31].”
BackgroundSelf-citationMultiple roles of TDP-43 in gene expression, splicing regulation, and human disease
Buratti, E. (2008) · Frontiers in Bioscience · doi:10.2741/2727 · Cited by 491 · cited 1×
“Although the normal biological functions of TDP-43 are not yet fully understood, it has been implicated in transcriptional repression, exon splicing, and possibly miRNA generation, cell cycle regulation and apoptosis [16].”
BackgroundTDP-43 Binds Heterogeneous Nuclear Ribonucleoprotein A/B through Its C-terminal Tail
Buratti, E., Brindisi, A., Giombi, M., Tisminetzky, S., Ayala, Y. M., & Baralle, F. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505557200 · Cited by 460 · cited 1×
“TDP-43 has been found to functionally interact with both hnRNP A1 and hnRNP A2/B1”
BackgroundNovel Mutations in TARDBP (TDP-43) in Patients with Familial Amyotrophic Lateral Sclerosis
Rutherford, N. J., Zhang, Y.-J., Baker, M., Gass, J. M., Finch, N. A., Xu, Y.-F., Stewart, H., Kelley, B. J., Kuntz, K., Crook, R. J. P., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000193 · Cited by 455 · cited 6×
“Furthermore, studies using a range of immortalized cell lines expressing either wild-type or mutant TDP-43 suggested that proteasome inhibition accelerates TDP-43 accumulation and insolubility [20,40,64,65,66].”
BackgroundResultInfluentialClinical limits of amyotrophic lateral sclerosis.
Mulder, D. W. (1982) · PubMed · Cited by 440
Johnson, B. S., McCaffery, J. M., Lindquist, S., & Gitler, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802082105 · Cited by 411 · cited 1×
“Cell culture, as well as yeast and animal models have provided insights into TDP-43 pathology [17,18,20,40,41,42].”
BackgroundTDP ‐ 43 mutation in familial amyotrophic lateral sclerosis
Yokoseki, A., Shiga, A., Tan, C., Tagawa, A., Kaneko, H., Koyama, A., Eguchi, H., Tsujino, A., Ikeuchi, T., Kakita, A., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21392 · Cited by 373 · cited 1×
“A pathogenic role for TDP-43 in disease is supported by the identification of mutations in TARDBP in familial and sporadic ALS [17,18,19,20,21,22,23].”
BackgroundProgranulin Mediates Caspase-Dependent Cleavage of TAR DNA Binding Protein-43
Zhang, Y.-J., Xu, Y.-F., Dickey, C. A., Buratti, E., Baralle, F., Bailey, R., Pickering-Brown, S., Dickson, D., & Petrucelli, L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3421-07.2007 · Cited by 371 · cited 2×
“For example, fragmentation of TDP-43 in cell culture has been induced by staurosporine [55,56] as well as TG [57].”
BackgroundCdh1-APC Controls Axonal Growth and Patterning in the Mammalian Brain
Konishi, Y., Stegmüller, J., Matsuda, T., Bonni, S., & Bonni, A. (2004) · Science · doi:10.1126/science.1093712 · Cited by 363
Deng, H., Zhai, H., Bigio, E. H., Yan, J., Fecto, F., Ajroud, K., Mishra, M., Ajroud‐Driss, S., Heller, S., Sufit, R., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22051 · Cited by 352 · cited 7×
“Fixed cells were permeabilized with 0.2% Triton X in PBS for 5 minutes and blocked for 1 hour in 3%BSA/2% heat-inactivated goat serum (Sigma) in PBS. Cells were stained overnight at 4uC with primary antibodies to: TDP-43 (1:400, Proteintech), phosphorylated TDP-43 Ser403/4 (1:1000, CosmoBio) hnRNP A1 and hnRNP A2/B1 (…”
BackgroundInfluentialTARDBP mutations in motoneuron disease with frontotemporal lobar degeneration
Benajiba, L., Le Ber, I., Camuzat, A., Lacoste, M., Thomas‐Anterion, C., Couratier, P., Legallic, S., Salachas, F., Hannequin, D., Decousus, M., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21612 · Cited by 303 · cited 1×
“tions in TARDBP have been reported in a number of patients with FTLD plus ALS [32,33,34,35].”
BackgroundTau Pathology in Two Dutch Families with Mutations in the Microtubule-Binding Region of Tau
Spillantini, M. G., Crowther, R. A., Kamphorst, W., Heutink, P., & van Swieten, J. C. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65721-5 · Cited by 292 · cited 2×
“Hence, FTLD-U cases with inclusions consisting of the protein TAR DNA-binding protein 43 (TDP-43) are termed FTLD-TDP, in contrast to FTLD-tau with tau inclusions, FTLD-FUS with inclusions containing fused in sarcoma (FUS) protein, and a smaller group of cases with deposits of unknown content termed FTLD-ubiquitin pro…”
BackgroundGötz, J., Streffer, J. R., David, D., Schild, A., Hoerndli, F., Pennanen, L., Kurosinski, P., & Chen, F. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001508 · Cited by 274 · cited 1×
“This assisted in the development of both cell culture and animal models to investigate tau-related pathomechanisms [28,29,30,31].”
BackgroundSelf-citationParkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia
Ittner, L. M., Fath, T., Ke, Y. D., Bi, M., van Eersel, J., Li, K. M., Gunning, P., & Götz, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808084105 · Cited by 223 · cited 1×
“Protein extracts were analyzed by immunoblotting, which was performed as previously described [69,70].”
MethodSelf-citationPrimary support cultures of hippocampal and substantia nigra neurons
Fath, T., Ke, Y. D., Gunning, P., Götz, J., & Ittner, L. M. (2009) · Nature Protocols · doi:10.1038/nprot.2008.199 · Cited by 215 · cited 2×
“Neuronal cell lines have been instrumental in studying both physiological and pathological processes in neurodegeneration [51].”
BackgroundMethodSelf-citationAbnormal phosphorylation of Ser409/410 of TDP‐43 in FTLD‐U and ALS
Inukai, Y., Nonaka, T., Arai, T., Yoshida, M., Hashizume, Y., Beach, T. G., Buratti, E., Baralle, F. E., Akiyama, H., Hisanaga, S.-I., et al. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.07.027 · Cited by 214 · cited 1×
“The inclusions in FTLDTDP and ALS contain both phosphorylated and ubiquitinated TDP-43 [11,53,54].”
BackgroundDegradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system
Wang, X., Fan, H., Ying, Z., Li, B., Wang, H., & Wang, G. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.055 · Cited by 207 · cited 1×
“Furthermore, studies using a range of immortalized cell lines expressing either wild-type or mutant TDP-43 suggested that proteasome inhibition accelerates TDP-43 accumulation and insolubility [20,40,64,65,66].”
BackgroundThe Pathobiology of Amyotrophic Lateral Sclerosis: A Proteinopathy?
Strong, M. J., Kesavapany, S., & Pant, H. C. (2005) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000173889.71434.ea · Cited by 206 · cited 1×
“ALS often leads to death within three years of diagnosis [1,2].”
BackgroundPathologically proven frontotemporal dementia presenting with severe amnesia
Graham, A. (2005) · Brain · doi:10.1093/brain/awh348 · Cited by 203 · cited 1×
“In contrast to Alzheimer’s disease, memory deficits are less common in FTLD [7,8].”
TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea
Kovacs, G. G., Murrell, J. R., Horvath, S., Haraszti, L., Majtenyi, K., Molnar, M. J., Budka, H., Ghetti, B., & Spina, S. (2009) · Movement Disorders · doi:10.1002/mds.22697 · Cited by 198 · cited 1×
“tions in TARDBP have been reported in a number of patients with FTLD plus ALS [32,33,34,35].”
BackgroundContribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis
Daoud, H., Valdmanis, P. N., Kabashi, E., Dion, P., Dupré, N., Camu, W., Meininger, V, & Rouleau, G. A. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.062463 · Cited by 194 · cited 1×
“A pathogenic role for TDP-43 in disease is supported by the identification of mutations in TARDBP in familial and sporadic ALS [17,18,19,20,21,22,23].”
BackgroundDeroo, B. J., Rentsch, C., Sampath, S., Young, J., DeFranco, D. B., & Archer, T. K. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4113-4123.2002 · Cited by 164 · cited 1×
“Interestingly, proteasome inhibition is known to change the subcellular localization of a range of proteins in processes like centrosome recruitment and nuclear translocation [58,59,60,61,62].”
BackgroundMackenzie, I. R. A., & H. Feldman, H. (2005) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000174335.27708.0a · Cited by 161 · cited 2×
“In comparison, frontotemporal lobar degeneration (FTLD) is a heterogeneous group of neurodegenerative disorders, clinically characterized by behavioral changes and/or language abnormalities, which may also be accompanied by motor symptoms, such as parkinsonism [3,4] or ALS [3,5].”
BackgroundGitcho, M. A., Bigio, E. H., Mishra, M., Johnson, N., Weintraub, S., Mesulam, M., Rademakers, R., Chakraverty, S., Cruchaga, C., Morris, J. C., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0571-7 · Cited by 161 · cited 1×
“tions in TARDBP have been reported in a number of patients with FTLD plus ALS [32,33,34,35].”
BackgroundTwo German Kindreds With Familial Amyotrophic Lateral Sclerosis Due to TARDBP Mutations
Kühnlein, P., Sperfeld, A.-D., Vanmassenhove, B., Van Deerlin, V., Lee, V. M.-Y., Trojanowski, J. Q., Kretzschmar, H. A., Ludolph, A. C., & Neumann, M. (2008) · Archives of Neurology · doi:10.1001/archneur.65.9.1185 · Cited by 159 · cited 1×
“A pathogenic role for TDP-43 in disease is supported by the identification of mutations in TARDBP in familial and sporadic ALS [17,18,19,20,21,22,23].”
BackgroundSalomon, D., Sacco, P. A., Roy, S. G., Simcha, I., Johnson, K. R., Wheelock, M. J., & Ben-Ze'ev, A. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.5.1325 · Cited by 157
Dormann, D., Capell, A., Carlson, A. M., Shankaran, S. S., Rodde, R., Neumann, M., Kremmer, E., Matsuwaki, T., Yamanouchi, K., Nishihara, M., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06211.x · Cited by 156 · cited 2×
“The latter may be supported by the finding that TDP-43 phosphorylation is a late event in a cellular disease model, and therefore not a prerequisite for its aggregation [55].”
BackgroundIttner, L. M., Ke, Y. D., & Götz, J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014472 · Cited by 156 · cited 1×
“Protein extracts were analyzed by immunoblotting, which was performed as previously described [69,70].”
MethodSelf-citationMattsson, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.031566998 · Cited by 142 · cited 1×
“Interestingly, proteasome inhibition is known to change the subcellular localization of a range of proteins in processes like centrosome recruitment and nuclear translocation [58,59,60,61,62].”
BackgroundCharacterization of Alternative Isoforms and Inclusion Body of the TAR DNA-binding Protein-43
Nishimoto, Y., Ito, D., Yagi, T., Nihei, Y., Tsunoda, Y., & Suzuki, N. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.022012 · Cited by 140 · cited 1×
“Furthermore, studies using a range of immortalized cell lines expressing either wild-type or mutant TDP-43 suggested that proteasome inhibition accelerates TDP-43 accumulation and insolubility [20,40,64,65,66].”
BackgroundLoss of progranulin function in frontotemporal lobar degeneration
Cruts, M., & Broeckhoven, C. V. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.01.004 · Cited by 126 · cited 7×
“Since neurons are the primary cell type affected in FTLD-U and ALS, we tested the effects of proteasome inhibition on endogenous TDP-43 in primary cortical and hippocampal neurons or immortalized motor neurons.”
BackgroundInfluentialNonaka, T., Arai, T., Buratti, E., Baralle, F. E., Akiyama, H., & Hasegawa, M. (2009) · FEBS Letters · doi:10.1016/j.febslet.2008.12.031 · Cited by 118 · cited 1×
“Furthermore, studies using a range of immortalized cell lines expressing either wild-type or mutant TDP-43 suggested that proteasome inhibition accelerates TDP-43 accumulation and insolubility [20,40,64,65,66].”
BackgroundA90V TDP‐43 variant results in the aberrant localization of TDP‐43 in vitro
Winton, M. J., Van Deerlin, V. M., Kwong, L. K., Yuan, W., Wood, E. M., Yu, C.-E., Schellenberg, G. D., Rademakers, R., Caselli, R., Karydas, A., et al. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.05.024 · Cited by 113 · cited 2×
“Proteins were extracted from both primary cortical neurons and NSC-34 cells as previously described [50].”
MethodSuzuki, H., Lee, K., & Matsuoka, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.197483 · Cited by 111 · cited 1×
“For example, fragmentation of TDP-43 in cell culture has been induced by staurosporine [55,56] as well as TG [57].”
BackgroundTDP-43 Depletion Induces Neuronal Cell Damage through Dysregulation of Rho Family GTPases
Iguchi, Y., Katsuno, M., Niwa, J.-I., Yamada, S.-I., Sone, J., Waza, M., Adachi, H., Tanaka, F., Nagata, K.-I., Arimura, N., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.012195 · Cited by 101 · cited 2×
“Knockdown of TDP-43 induces cell death in Neuro-2a cells possibly through Rho family GTPases [67].”
Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias
Liscic, R. M., Storandt, M., Cairns, N. J., & Morris, J. C. (2007) · Archives of Neurology · doi:10.1001/archneur.64.4.535 · Cited by 84 · cited 1×
“In contrast to Alzheimer’s disease, memory deficits are less common in FTLD [7,8].”
Parkin is recruited to the centrosome in response to inhibition of proteasomes
Zhao, J., Ren, Y., Jiang, Q., & Feng, J. (2003) · Journal of Cell Science · doi:10.1242/jcs.00700 · Cited by 73 · cited 1×
“Interestingly, proteasome inhibition is known to change the subcellular localization of a range of proteins in processes like centrosome recruitment and nuclear translocation [58,59,60,61,62].”
BackgroundChiò, A., Calvo, A., Moglia, C., Restagno, G., Ossola, I., Brunetti, M., Montuschi, A., Cistaro, A., Ticca, A., Traynor, B. J., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.173 · Cited by 73 · cited 1×
“tions in TARDBP have been reported in a number of patients with FTLD plus ALS [32,33,34,35].”
BackgroundSantiago-Josefat, B., Pozo-Guisado, E., Mulero-Navarro, S., & Fernandez-Salguero, P. M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1700-1709.2001 · Cited by 65 · cited 1×
“Interestingly, proteasome inhibition is known to change the subcellular localization of a range of proteins in processes like centrosome recruitment and nuclear translocation [58,59,60,61,62].”
BackgroundEndosome-Lysosomes, Ubiquitin and Neurodegeneration
Mayer, R. J., Tipler, C., Arnold, J., László, L., Al-Khedhairy, A. A., Lowe, J. S., & Landon, M. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4613-0335-0_33 · Cited by 49 · cited 1×
“Pathological protein aggregates are frequently surrounded by proteasomes and lysosomes, however, these fail to fully remove the deposits [44,45].”
BackgroundThe complex aetiology of frontotemporal lobar degeneration
Pickering-Brown, S. M. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.03.017 · Cited by 46 · cited 1×
“In FTLD, where 40% of patients have a family history of neurological disease, other multiple chromosomal loci have been revealed [24].”
BackgroundIttner, L. M., Koller, D., Muff, R., Fischer, J. A., & Born, W. (2005) · Biochemistry · doi:10.1021/bi048111o · Cited by 44
Self-citationPhosphorylation of soluble tau differs in Pick’s disease and Alzheimer’s disease brains
van Eersel, J., Bi, M., Ke, Y. D., Hodges, J. R., Xuereb, J. H., Gregory, G. C., Halliday, G. M., Götz, J., Kril, J. J., & Ittner, L. M. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0293-y · Cited by 40
Self-citationKrupka, N., Strappe, P., Götz, J., & Ittner, L. M. (2010) · Plasmid · doi:10.1016/j.plasmid.2010.01.002 · Cited by 19 · cited 1×
“For lentiviral production, 293T human embryonic kidney cells were used to generate lentiviral packaging, whilst SH-SY5Y cells were used for tittering of viral stocks, as previously described [72].”
MethodSelf-citation
Cited by
ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair
Klim, J. R., Williams, L. A., Limone, F., Guerra San Juan, I., Davis-Dusenbery, B. N., Mordes, D. A., Burberry, A., Steinbaugh, M. J., Gamage, K. K., Kirchner, R., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0300-4 · Cited by 653
Protein aggregation in amyotrophic lateral sclerosis
Blokhuis, A. M., Groen, E. J. N., Koppers, M., van den Berg, L. H., & Pasterkamp, R. J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1125-6 · Cited by 579
“Consistently, proteasome inhibition has been found to increase endogenous TDP-43 levels, blocks degradation of overexpressed TDP-43 C-terminal fragments and enhances toxicity [88, 155, 194, 220].”
BackgroundRNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43
Mann, J. R., Gleixner, A. M., Mauna, J. C., Gomes, E., DeChellis-Marks, M. R., Needham, P. G., Copley, K. E., Hurtle, B., Portz, B., Pyles, N. J., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.048 · Cited by 537
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis
Suk, T. R., & Rousseaux, M. W. C. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00397-1 · Cited by 450
TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets
Scotter, E. L., Chen, H.-J., & Shaw, C. E. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0338-x · Cited by 382
“Enhanced levels of TDP-43 in the cytoplasm can occur downstream of ALS-linked mutations [16, 39, 60, 145, 146], cellular stress [20, 136–138], or impaired degradation [147].”
Metadata
- Authors
- van Eersel, J., Ke, Y. D., Gladbach, A., Bi, M., Götz, J., Kril, J. J., & Ittner, L. M.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Ittner, Lars M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-07-29
- Volume
- 6
- Issue
- 7
- Pages
- e22850
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3146516
- OpenAlex
- W2088821814
- Cited by
- 130
- References
- 73
- Citations by year
- 2026: 15 · 2025: 9 · 2024: 12 · 2023: 9 · 2022: 6 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 8 · 2017: 5 · 2016: 10 · 2015: 9 · 2014: 9 · 2013: 11 · 2012: 4
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Science Council
- Medical Research Council
- Australian Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- TDP-43, proteasome inhibition, cytoplasmic accumulation, protein aggregation, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, neuronal stress, TDP-43 phosphorylation, ubiquitination, motor neurons, hippocampal neurons, cortical neurons, neurodegeneration
- MeSH terms
- Animals, Cell Nucleus, Cells, Cultured, Cytoplasm, DNA-Binding Proteins, Humans, Immunoenzyme Techniques, Leupeptins, Neurons, Phosphorylation, RNA, Messenger, Subcellular Fractions, Blotting, Western, Cysteine Proteinase Inhibitors, Cell Death, RNA, Small Interfering, Immunoprecipitation, Mice, Ubiquitination, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.